Orient Pharmaceutical Co., Ltd. 2025 independent directors’ performance report (Su Weike)
Orient Pharmaceutical Co., Ltd.
2025 Independent Directors’ Work Report
(Su Weike)
As an independent director of Orient Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), I strictly follow the provisions and requirements of the "Company Law", "Securities Law", "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations", "Listed Company Governance Guidelines" and other relevant laws, regulations, normative documents, and the company's "Articles" and "Independent Director Work Rules" in 2025. He diligently performs his duties every year and faithfully performs his duties. With his rich professional knowledge and experience, he actively participates in the meetings of the company's board of directors and special committees and shareholders' meetings. He performs his duties in the daily work and decision-making of the board of directors. He expresses independent and objective opinions on major matters reviewed by the board of directors, provides support for the scientific decision-making of the board of directors, promotes the company's standardized operations, and effectively protects the rights and interests of all shareholders from being harmed. I would like to report my performance of duties in 2025 as follows:
1. Basic information and independence description of independent directors
(1) My work history, professional background and part-time job status
As an independent director of the company, I have professional qualifications and abilities, and have accumulated rich experience in the professional fields in which I am engaged. My personal work resume, professional background and part-time employment status are as follows:
I am Su Weike, born in 1961, a member of the Kuomintang Revolutionary Party, with a doctoral degree. I have been a professor at Zhejiang University of Technology since July 2001. I have presided over or been responsible for the completion of more than 10 national projects and more than 20 provincial and ministerial projects such as the National Key Research and Development Plan, the "973" Frontier, the "11th Five-Year Plan" Science and Technology Support Plan, and major international cooperation. More than 30 major scientific and technological achievements have been industrialized. Obtained 1 Category 3·1 API approval document and 2 new drug clinical approval documents. Chief editor of "Preparation Methods of Pharmaceutical Intermediates" (Chemical Industry Press, 2001), co-editor of "Ball Milling Towards Green Synthesis Applications, Projects, Challenges." (The Royal Society of Chemistry. UK, 2015), published more than 200 papers included in SCI, and authorized more than 100 invention patents. He has won 1 second-class national scientific and technological invention award, 7 first-class provincial and ministerial-level scientific and technological achievement awards, and 3 Chinese Patent Excellence Awards. He was awarded the title of Zhejiang Province Special Expert and Zhejiang Province Expert with Outstanding Contribution. In 2014, he won the National May Day Labor Certificate and enjoyed special government allowances from the State Council. During the reporting period, he concurrently served as an independent director of the listed companies Zhejiang Yangfan New Materials Co., Ltd. and Zhejiang Zhongxin Fluorine Materials Co., Ltd. He is currently an independent director of the company.
(2) Description of independence of independent directors
As an independent director of the company, I have not held any position in the company other than as an independent director, nor have I held any position in the company's major shareholder company. I have no interest relationship with the company or major shareholders or other relationships that may hinder its independent and objective judgment. This is in compliance with the relevant requirements for the independence of independent directors in the "Measures for the Administration of Independent Directors of Listed Companies" and "Shanghai Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies No. 1 - Standardized Operations".
2. Annual performance of duties
(1) Attendance at meetings
- Attendance at the board of directors and shareholders’ meetings during the reporting period
Participating shareholders’ participation in the board of directors
Information about the status of the independent board of directors meeting should be attended this year. Whether the shareholder attended in person or by proxy for two consecutive days was absent.
Name Participated by joining the board of directors No. of meetings without attending in person No. of meetings No. of meetings
Times Add times Add meetings Shusuweike 6 6 6 0 0 No 1
- Participation in the work of special committees of the board of directors and special meetings of independent directors during the reporting period
Participation in special committees of the Board of Directors Special meetings of independent directors Independent directors
Audit Nomination Strategy Remuneration and Examination Names attending special meetings of independent directors
Committee Committee Committee Nuclear Committee Number of times
Su Weike 4 0 / / 0
Note: 1. “/” indicates that you are not a member of the committee and do not need to attend the meeting;
- During the reporting period, the company's management structure was stable, and no matters requiring the convening of the Nomination Committee occurred; 3. During the reporting period, no matters requiring the convening of special meetings of independent directors occurred.
As an independent director of the company, I strictly follow the requirements of relevant laws and regulations. Before the board of directors and its committees convene, I carefully review the meeting materials provided by the company, proactively inquire and understand the situation and information that needs to be mastered, actively participate in the discussion of various proposals, give full play to the advantages of my respective professional knowledge and work experience, and put forward reasonable opinions and suggestions. At the same time, he exercised his voting rights independently and objectively, and voted in favor of all proposals reviewed by the Board of Directors and its committees.
(2) Exercising the powers of independent directors
During the reporting period, as an independent director of the company, I did not exercise my authority to propose convening a board of directors or propose to the board of directors to convene an extraordinary general meeting of shareholders, independently hire an intermediary agency, or publicly solicit shareholder rights from shareholders.
(3) Communication with internal audit institutions and accounting firms
During the reporting period, as an independent director, I actively communicated with the company's internal audit institution and accounting firm, and communicated with the accounting firm to confirm the personnel composition, audit plan, risk judgment and audit focus of the 2025 annual audit project team, ensuring that the audit work was carried out in a reasonable and orderly manner, maintaining the objectivity and fairness of the audit results, and effectively performing the external supervision responsibilities of the independent directors.
(4) Communication with small and medium-sized shareholders
During the reporting period, I took advantage of opportunities such as attending shareholder meetings to communicate with small and medium-sized shareholders, understand their opinions and demands, and effectively safeguard the legitimate rights and interests of shareholders, especially small and medium-sized shareholders.
(5) Situation of working on-site at the company
During the reporting period, I paid close attention to the company's operation, management and financial status, listened to the company's management's reports on the operation and progress of major events in a timely manner, and conducted on-site inspections of the company's rooftop headquarters and Hangzhou R&D center to understand the progress of the construction of convertible bond investment projects and the latest developments in the company's R&D progress. At the same time, I participated in the company's board of directors and special committees through online meetings, and gained an in-depth understanding of the company's operation and management and the progress of major matters; I kept in close contact with the company's directors and senior managers through phone calls, WeChat and emails, etc., and kept informed of the progress of the company's major matters, grasped the company's operating dynamics, and effectively performed the duties of an independent director.
(6) Listed companies’ cooperation with independent directors
As an independent director, I have received active cooperation from the company in carrying out relevant work. The company promptly issues board meeting notices and meeting materials to me, and provides effective communication channels. In principle, board of directors and special committee meetings are held on-site, and provides communication methods for participation. The secretary of the board of directors and the securities legal department actively provide assistance to independent directors in performing their duties. When I exercised my powers as an independent director, relevant personnel of the company actively cooperated, and there was no refusal, obstruction or concealment, or interference in the exercise of my powers by independent directors.
3. Matters of focus in annual performance of duties by independent directors
(1) Related transactions
During the reporting period, the company had no related party transactions that should be disclosed but failed to do so.
(2) Fulfillment of commitments by the company and shareholders
During the reporting period, the company and shareholders did not violate their commitments.
(3) Disclosure of financial information and internal control evaluation reports in financial accounting reports and periodic reports
The financial information in the company's financial accounting reports and periodic reports fairly reflects the company's financial status and operating results during the relevant reporting period, and there are no false records, misleading statements or major omissions; the company has maintained effective internal control over financial reporting in all major aspects in accordance with the requirements of the corporate internal control standard system and relevant regulations, and no major defects in financial reporting and non-financial reporting internal control have been found.
(4) Appointment and dismissal of accounting firms that undertake the audit business of listed companies
During the reporting period, the company held the 15th meeting of the third board of directors and the first extraordinary general meeting of shareholders in 2025, which reviewed and approved the "Proposal on Engaging the Company's 2025 Audit Institution" and agreed to appoint Grant Thornton Accounting Firm (Special General Partnership) (hereinafter referred to as "Grant Thornton") as the company's 2025 audit institution to provide the company with 2025 audit services. Before this matter was submitted to the Board of Directors for consideration, it had been reviewed and approved by the Audit Committee of the Board of Directors. I have focused on Grant Thornton's qualifications, independence, professionalism, effectiveness of the audit process, and audit fees. It has the qualifications to practice securities and futures-related businesses, has the professional ability and qualifications for auditing, and the audit fees are reasonable and can meet the company's annual audit requirements.
(5) Appointment or dismissal of financial officers of listed companies
During the reporting period, the company did not appoint or dismiss financial personnel.
(6) Changes in accounting policies, accounting estimates or correction of major accounting errors due to reasons other than changes in accounting standards
During the reporting period, the company did not make any changes in accounting policies, accounting estimates or correction of major accounting errors due to reasons other than changes in accounting standards.
(7) Nominate or appoint or remove directors, hire or dismiss senior managers
During the reporting period, Mr. Li Jinliang resigned as a director of the company due to work adjustment, and was later elected as an employee representative director of the third session of the company's board of directors by the employees' congress.
(8) Remuneration of directors and senior managers, formulating or changing equity incentive plans and employee stock ownership plans, ensuring that incentive objects are granted rights and conditions for exercising rights and interests are met, and directors and senior managers arrange stock ownership plans in subsidiaries to be spun off
The formulation and approval procedures for the remuneration plans of the company's directors and senior managers comply with relevant regulations. During the reporting period, the company's 2022 Restricted Stock Incentive Plan's third lifting period of restricted sales was met with the conditions for lifting the restricted sales.
(9) Usage of raised funds
I have supervised and reviewed the use of the company's raised funds in accordance with relevant regulations such as the "Supervision Rules for Listed Companies' Raised Funds", "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations", the company's "Management System for the Use of Raised Funds" and other relevant regulations. As of December 31, 2025, the specific use of the company's raised funds is consistent with the company's disclosed situation. There is no disguised change in the use of raised funds and harm to the interests of shareholders, and there is no illegal use of raised funds.
4. Overall evaluation and suggestions
In 2025, I diligently performed my duties as an independent director, actively and effectively performed my duties as an independent director, exercised my voting rights independently, prudently and objectively, and effectively safeguarded the overall interests of the company and the legitimate rights and interests of all shareholders. I have actively and effectively performed my duties as an independent director. For major matters reviewed by the company's board of directors, I require the company to notify relevant matters in advance in accordance with the provisions of the Articles of Association and provide complete finalized materials.
In 2026, I will continue to work diligently, strengthen my studies, continue to improve my ability to perform my duties, provide reference opinions for the board of directors' scientific decision-making, and better safeguard the legitimate rights and interests of the company and all shareholders. This is reported.
Independent Director: Su Weike
April 15, 2026